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The control of micrometastatic breast cancer remains problematic. To this end, we are developing a new adjuvant therapy based on
213Bi-PAI2, in which an a-emitting nuclide (
213Bi) is chelated to the plasminogen activator inhibitor-2 (PAI2). PAI2 targets the cell-
surface receptor bound urokinase plasminogen activator (uPA), which is involved with the metastatic spread of cancer cells. We have
successfully labelled and tested recombinant human PAI2 with the a radioisotope
213Bi to produce
213Bi-PAI2, which is highly
cytotoxic towards breast cancer cell lines. In this study, the 2-day postinoculation model, using MDA-MB-231 breast cancer cells, was
shown to be representative of micrometastatic disease. Our in vivo efficacy experiments show that a single local injection of
213Bi-
PAI2 can completely inhibit the growth of tumour at 2 days postcell inoculation, and a single systemic (i.p.) administration at 2 days
causes tumour growth inhibition in a dose-dependent manner. The specific role of uPA as the target for
213Bi-PAI2 therapy was
determined by PAI2 pretreatment blocking studies. In vivo toxicity studies in nude mice indicate that up to 100mCi of
213Bi-PAI2 is
well tolerated. Thus,
213Bi-PAI2 is successful in targeting isolated breast cancer cells and preangiogenic cell clusters. These results
indicate the promising potential of
213Bi-PAI2 as a novel therapeutic agent for micrometastatic breast cancer.
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The major failure in the management of early breast cancer is the
incomplete killing of malignant cancer cells that have spread
throughout the body (Allen, 1999a). This is despite the many
treatments available, such as surgery, radiation therapy, hormone
therapy and chemotherapy. The American Cancer Society (2001)
estimated 182800 new cases of invasive breast cancer in the year
2000 among women in America, and 40800 are expected to die
from the disease (American Cancer Society, 2000). Novel, more
effective treatments that overcome this problem in breast cancer
management are essential. Targeted therapy, first discussed over
100 years ago, is based on the idea that a drug will attack its target
without damaging other tissue (Raso, 1990). Targeted alpha
therapy (TAT) uses an a-emitting radionuclide as a lethal
medicament via an effective targeting carrier to kill cancer cells
(McDevitt et al, 1998; Allen, 1999b). We are investigating a novel
targeting approach that exploits the involvement of cell-surface
receptor bound urokinase plasminogen activator (uPA) in the
metastatic spread of breast cancer cells (Kruithof et al, 1995).
a-emitting radionuclides emit a particles with energies of 4–
8MeV, which are up to an order of magnitude greater than most b
rays. Yet, their ranges are two orders of magnitude less as a
particles have a linear energy transfer (LET) which is about 100
times greater (Allen, 1999a). This is manifested by a higher relative
biological effectiveness (RBE). As a result, a much greater fraction
of the total energy is deposited in cells with a’s and very few
nuclear hits are required to kill a cell. Consequently, only a
radiation has the potential to kill the metastatic cancer cells at
tolerable dose limits, whereas the low LET of b’s makes this a very
difficult task within human dose tolerance limits.
Availability of the a-emitting radionuclides has been the major
problem in the past for their large-scale scientific and clinical
application. Studies have been carried out using
149Tb (Allen,
1999a; Rizvi et al, 2001),
211At (Bloomer et al, 1984; Larsen et al,
1998) and
212Bi (Macklis et al, 1993; Horak et al, 1997) with
encouraging results. The stable and reliable
225Ac generator of the
a emitting nuclide
213Bi has been produced, modified and used
successfully, with several of these studies indicating a therapeutic
potential of
213Bi-labelled antibody constructs against cancer cells
both in vitro and in vivo (Van Geel et al, 1994; Boll et al, 1998;
Kennel, 1999a,b; McDevitt et al, 1999; Nikula et al, 1999; Adams
et al, 2000; McDevitt et al, 2000). Our group has modified methods
of conjugating
213Bi radionuclide to antibodies with the stable
chelator cyclic diethylenetriaminepentacetic acid anhydride
(cDTPA) for use in the a therapy of melanoma (Rizvi et al, 2000;
Allen et al, 2001a, b), colorectal cancer (Rizvi et al, 2001),
leukaemia (Rizvi et al, 2002), breast (Ranson et al, 2002) and
prostate cancer (Li et al, 2002a,b).
A large body of experimental and clinical evidence implicates
overexpression of the urokinase plasminogen activator (uPA)
system as a modulator of the aggressive behaviour of cancer cells
and as a strong prognostic factor for predicting poor breast cancer
patient outcome (Pollanen et al, 1991; Andreasen et al, 1997;
Schmitt et al, 2000). uPA converts plasminogen into the highly
active protease plasmin. Plasmin promotes tissue degradation and
remodelling of the local extracellular environment by directly
and indirectly (via activation of prometalloproteases) degrading
extracellular matrix molecules. uPA is synthesised and secreted as
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sa proenzyme, whose activation is markedly accelerated upon
binding with high affinity (0.1–1nM) to specific cell-surface uPA
receptors (uPAR) (Pollanen et al, 1991; Schmitt et al, 1992).
Receptor density varies depending on cell type (10
3–10
6
sitescell
 1; Schmitt et al, 1992). The ability of PAI2 to inhibit
tumour invasion and metastases in animal models has been
demonstrated by several laboratories utilising uPA-overexpressing
cancer cells (Ranson et al, 2002).
PAI1 conjugated to A-chain cholera toxin as the cytotoxic agent
or modified PAI1 conjugated to saporin has been used to target
fibrosarcoma cells (Jankun, 1992, 1994) with moderate cytotoxi-
city. However, PAI2 has several distinct advantages over PAI1 for
targeted cancer therapy, as discussed in Ranson et al (2002). Cell
surface-bound uPA is accessible to and inhibitable by exogenous
PAI2 (Jankun, 1992; Yang et al, 2000), and a number of studies
have suggested the potential for PAI2 to inhibit cancer cell
invasion and metastasis (Kruithof et al, 1995).
The pharmacokinetics and biodistribution of human recombi-
nant
125I-labelled PAI2 in both control mice and mice bearing
human colon cancer (uPA-positive HCT116 cell line) xenografts
have been established (Hang et al, 1998). Such studies indicate that
invasive and metastatic tumour cells, shown consistently to
contain active uPA, would be accessible to and targeted by
exogenously administered PAI2.
It is clear that uPA is a specific marker of malignancy and that
PAI2 represents a useful targeting agent. We have previously
reported the production and evaluation of the new a-nuclide
emitting cytotoxic agent
213Bi-labelled PAI2 (Ranson et al, 2002).
The reactivity, specificity and cytotoxicity of a-PAI2 were reported
for both MDA-MB-231 and MCF-7 human breast cancer cell lines
in vitro. Immunohistochemistry mirrored the differences in
expression of endogenous uPA and uPAR antigen seen in these
two cell lines by flow cytometry (Ranson et al, 2002).
We have also carried out in vitro and in vivo studies of
213Bi-
PAI2 for prostate cancer (Li et al, 2002b), finding it to be
efficacious within the maximum tolerance dose limits. We now
demonstrate the efficacy of TAT with
213Bi-PAI2 in a nude mouse
breast cancer model, using MDA-MB-231 breast cancer cells. These
data clearly show that
213Bi-PAI2 has an important role as a
potential new therapeutic modality for the control of microme-
tastases in breast cancer.
MATERIALS AND METHODS
Human recombinant PAI2 (47kDa) was provided by Biotech
Australia Pty Ltd RPMI-1640 was purchased from Life Technol-
ogies (Castle Hill, NSW, Australia). Fetal calf serum (FCS) was
obtained from Trace Bioscientific (Castle Hill, NSW, Australia).
The cyclic anhydride of diethylenetriaminepentacetic acid
(cDTPA) was purchased from Aldrich Chemical Company, bovine
serum albumin (fraction V) (BSA) from Sigma Chemical (St Louis,
MO, USA), and mouse anti-human uPA IgG1 (#394) monoclonal
antibody (MAb) from American Diagnostica Inc. (Greenwich, CT,
USA). Mouse isotype control subclasses IgG1 MAb was from
Silenus (Sydney, NSW, Australia) and rabbit anti-mouse IgG and
alkaline phosphatase and anti-alkaline phosphatase (APAAP) were
purchased from Dakopatts (Glostrap, Denmark). Mouse anti-
human melanoma IgG2a MAb (9.2.27) used as a nonspecific
control was kindly provided by the Royal Newcastle Hospital
(Sydney, Australia).
Radioisotope
a-particle-emitting radionuclide
213Bi was produced from the
225Ac/
213Bi generator, purchased from the United States Depart-
ment of Energy, Oak Ridge National Laboratory (Oak Ridge, TN,
USA).
213Bi was eluted from the
225Ac column with 250mLo f
freshly prepared 0.15 M distilled and stabilised hydriodic acid
followed by washing with 250mL sterile distilled water (Boll et al,
1997). The first elution was not used, and a time of 2h was allowed
for
213Bi to regenerate on the column for the next elution. Activity
corrections were made for
213Bi decay using the half-life of 46min.
PAI2 conjugation with cDTPA, stoichiometry and
reactivity
PAI2 and BSA were conjugated with cDTPA by a modification of
published methods to give the desired protein-DTTA conjugate
(Ranson et al, 2002) while MAb 9.2.27 was conjugated with cDTPA
as described previously (Rizvi et al, 2000) for nonspecific control.
The concentrations of the protein-DTTA chelates were mea-
sured by BIORAD DC protein assay reagent kit (Pierce, Rockford
Il, USA). The stoichiometry of DTTA-PAI2 was determined using
electrospray ionisation mass spectrometry as previously described
(Ranson et al, 2002). The DTTA-PAI2 was diluted in 1:20 in water
and then 1:2 with 50% MeOH and 1% acetic acid.
213Bi labelling of DTTA-PAI2
Concentrated DTTA-PAI2 stocks were diluted with 500mM sodium
acetate at pH 5.5 and 5–10mg of DTTA-PAI2 was labelled with free
213Bi for 20min at room temperature as described previously
(Ranson et al, 2002). The radiolabelling efficiency was about 90%,
as determined by instant thin layer chromatography (ITLC) using
the described method (Rizvi et al, 2000; Ranson et al, 2002).
Serum stability study
213Bi-PAI2 was incubated in fresh human serum and in DTPA
(challenge test) at 371C over 24h. Activity was counted by
detecting the 440keV gamma ray from the decay of
213Bi. The
percentage leaching/stability was calculated as a function of time,
and the results were corrected for decay of the radioisotope.
Cell culture
The metastatic MDA-MB-231 human breast cancer cell line was
originally purchased from American Type Culture Collection
(Rockville, MD, USA) and routinely cultured in RPMI-1640
supplemented with 10% (vv) heat-inactivated FCS and passaged
using trypsin/EDTA. The cells were incubated in a humidified
incubator at 371C with a 5% carbon dioxide air atmosphere. For all
experimental procedures, subconfluent cells that had been in
culture for 48h without a change of media were harvested by
rinsing flasks twice with PBS (pH 7.2) and then detaching with
PBS/0.5mM EDTA at 371C for 5min. Cells were collected and
resuspended in the appropriate buffer as described below.
Animals and MDA-MB-231 cell inoculation
In all, 6 to 8-week-old athymic nude mice, BALB/c (nu/nu) female
mice were purchased from Animal Resources Centre (ACR),
Western Australia. The mice were housed and maintained in
laminar flow cabinets under specific pathogen-free conditions in
facilities approved by the University of New South Wales (UNSW)
Animal Care and Ethics Committee (ACEC) and in accordance
with their regulations and standards. The ethical guidelines that
were followed meet the standards required by the UK Coordinating
Committee on Cancer Research Guidelines (Workman et al, 1998).
To establish s.c. animal tumour models, 1 million MDA-MB-231
cells were resuspended in 200mL of RPMI-164 serum-free medium
and injected via an 18-gauge needle into bilateral mammary fat
pads of each nude mouse. Tumour progression was documented
once weekly by measurements using calipers, and tumour volumes
were calculated by the following formula: length width 
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sheight 0.52 in millimetres (Gleave et al, 1991). All mice were
killed when the xenografts approached 1 1cm
2 in area by CO2
chamber.
Control injections used PBS and the nonspecific a-conjugates
213Bi-BSA and
213Bi-9.2.27 (monoclonal antibody for melanoma).
Experimental protocols
In vivo toxicity study: Groups of five mice received a total injected
activity (bound plus unbound
213Bi) of 1.5, 3 and 6mCi/kg weight
dose of
213Bi-PAI2 by i.p. injection. Additional mice were treated
with PAI2, cDTPA and PBS as controls. Mice were monitored and
weight was measured.
Biodistribution study: Mice received an i.p injection of
213Bi-
PAI2, and were euthanised at 15, 30, 45, 60, 90 and 120min.
Tissues and organs were removed, weighed and the activity was
counted. The bone marrow count was obtained by measuring
activity in the hip. Results are quoted as percent activity at a given
euthanasia time.
Two-day MDA-MB-231 model: One million cells were injected
s.c. into bilateral mammary glands of five mice, and at 2 days the
mice were killed and the local tissue section removed for
histochemistry. The objective of this study was to demonstrate
the state of pretumour development.
Local TAT efficacy for dose response: Efficacy studies of local
TAT were made for dose response and for postinoculation time
response at 2 days postinoculation. The
213Bi-PAI2 was injected in
the same region as the inoculation, as no tumour was evident.
Local TAT efficacy for time response: Four different therapy time
points were used, each with five mice: 2–4, 7, 14 and 28 days after
cell inoculation. Each group had one control mouse and four
treated mice.
Systemic TAT with
213Bi-PAI2: The dose response for systemic
administration (i.p.) injection at 2 days postinoculation was also
studied. Previous studies had shown little difference between i.p.
and tail vein injections, so the more difficult tail vein approach was
not justified.
PAI2 blocking study: At 2 days postbilateral inoculation each of
10
6 cancer cells, i.p. administration at two, three and four times the
standard PAI2 conjugate concentration (100mgmL
 1) was fol-
lowed by 100mCi of
213Bi-PAI2 in groups of five mice. Tumour
growth was monitored in all mice and mice were killed at the
tumour volume limit.
Statistics
All numerical data were expressed as the average of the values
obtained, and the standard error of means (s.e.m.) was calculated
and shown in the figures. Unpaired t-test was used to determine
significant differences at 0.05 probability between tumour growth
expressed as volume for controls and
213Bi-PAI2-treated mice.
Immunohistochemistry
The alkaline phosphatase antialkaline phosphate (APAAP) method
was used to detect uPA expression in MDA-MB-231 cells after 2
days inoculation in nude mice (Li et al, 2002b). Control slides were
treated in an identical manner. PC3 metastatic prostate cancer cells
were chosen as a positive control, while isotype MAb or the
primary antibody were omitted as a negative control. The positive
cells appear pink.
RESULTS
Chelation of PAI2 with cDTPA
Mass spectroscopy results are shown in PAI2 alone (Figure 1A)
and DTTA-PAI2 (Figure 1B). Up to five-fold attachment of cDTPA
is observed, the peaks being separated by the MW of the chelator
(357Da).
Serum stability test
Most of the instability of
213Bi-PAI2 in serum and in DTPA
(challenge test) occurs within one half-life of
213Bi (data not
shown). Leaching of activity is in the range from 20 to 30%.
Curiously, the conjugate is more stable in the DTPA challenge.
In vivo tolerance study
The weights of injected mice reduced initially by 5–10%, then
recovered after 1 week. After 13 weeks, one saline control mouse
died, but other mice were healthy until euthanasia at 24 weeks
post-therapy (data not shown). No dose effect was observed.
Biodistribution
Results were obtained over 2.6 half-lives (Figure 2) and showed
that the kidneys received the highest activity, being more than
half the observed activity after 25min. The bone marrow receives
the next highest dose, but other organs have relatively low
exposure.
Expression of uPA in vivo model after 2 days inoculation
A group of five mice were sacrificed at 2 days after cell inoculation.
The results from immunostaining with the #394 MAb against uPA
show that isolated cells and cell clusters are prevalent, all cancer
cells are positive to uPA, and there is no evidence for
microcapillary formation (Figure 3A) while the cancer cells with
no primary MAb are negative to uPA MAb (Figure 3B). Thus the 2-
day model accurately simulates micrometastasis and preangio-
genic lesions.
Tumour growth inhibition by local injection of
213Bi-PAI2
In an earlier study (Allen et al, 2001a), local injection at 2 days
postinoculation of 12, 25 and 50mCi of
213Bi-PAI2 showed a dose-
dependent response in groups of five mice. Tumours grew quickly
after injection with a PBS control, while the 12mCi group grew very
slowly. The 25 and 50mCi groups showed complete inhibition of
tumour growth.
This study was repeated using bilateral injections of 50mCi of
213Bi-PAI2 and
213Bi-BSA (which has comparable mass to
213Bi-
PAI2) and PBS as controls. Results are shown in Figure 4A. Both
PBS and
213Bi-BSA controls are significantly different to the
213Bi-
PAI2 results (P¼0.04 and 0.03, respectively).
A single injection of
213Bi-PAI2 (25mCi) was made into cell
inoculation sites or tumours at different postinoculation times.
Mice were monitored and tumours were measured. The 2–4-day
group had the best response to the therapy, which had some 50%
(23 out of 40) tumour control and slower tumour growth rate
compared with control mice. The 7-day and 14-day groups had two
out of eight and one out of eight tumour control and slower growth
rate compared with control mice. The 28-day group had zero out
of eight tumour control and no obvious change in tumour growth
rate.
Efficacy of
213Bi-PAI2 by systemic injection
Mice received single systemic (i.p.) injections of 25, 50 and 100mCi
of
213Bi-PAI2 at 2 days postinoculation. The results indicate a
substantial inhibition of tumour growth up to 35 days post-
inoculation. The control mice (n¼5) received a single i.p.
injection of 100mCi nonspecific
213Bi-9.2.27 conjugate, which had
no effect on tumour growth (Figure 5A), while in the treated
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sgroups (n¼5), a dose effect is indicated in that increased activity
decreased the number of observed tumours, that is, three out of
five in 25mCi (Figure 5B), two out of five in 50mCi (Figure 5C)
and one out of five in 100mCi (Figure 5D). The control data
are significantly different from the
213Bi-PAI2 data for all dose
levels.
A second study was made with both PBS and
213Bi-BSA controls,
and the results are shown in Figure 4B. The controls are not
significantly different from each other, but the PBS and
213Bi-BSA
controls are significantly different from the
213Bi-PAI2 result
(P¼0.01 and 0.04, respectively). Note that only a single i.p.
injection of 100mCi was made.
PAI2 blocking study
Systemic (i.p.) injection of PAI2 at two, three and four times
213Bi-
PAI2 was administered, followed by the
213Bi-PAI2 conjugate.
Results are shown in Figure 4C, where tumours grew in all ‘PAI2
blocked’ mice, whereas eight out of 10 ‘unblocked’ mice showed
complete tumour growth inhibition to 60 days. Pretreated mice
showed tumour volumes that were not significantly different for
each concentration. However, they were all significantly different
to the ‘unblocked’ mice (Po0.001). The ‘blocked’ mice were
euthanised at 30–45 days according to protocol. All excess
concentrations of PAI2 were adequate to effectively block
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Figure 1 Chelation of PAI2 with cDTPA. Mass spectroscopy results for PAI2 (A) and DTTA-PAI2 (B). Multiple attachment of the chelator occurs, as is
evident by the peaks shifted by the MW¼357Da of the chelator cDTPA.
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sMDA-MB-231 breast cancer cells receptors at 2 days postbilateral
inoculation.
DISCUSSION
In this study, we describe the novel compound
213Bi-PAI2 and
show that it retains reactivity, selectivity and cytotoxicity towards
uPA expressing breast cancer cells in vivo. That
213Bi-PAI2
cytotoxicity is significantly mediated via a uPA-dependent
mechanism had been confirmed by the lack of cytotoxicity of
freshly isolated, normal human leukocytes on which cell-surface
localised active uPA was not detectable (Ranson et al, 2002).
213Bi-
PAI2 was found to be selectively toxic to targeted breast cancer
cells, whereas nontargeted cells are spared from the radiotoxicity
arising from the a radiation. Breast cancer cells incubated with a
nonspecific a-conjugate, viz
213Bi-BSA, were also minimally
affected.
Mass spectroscopy analyses show that multiple binding of the
cDTPA chelator occurs. While this will enhance the activity carried
by PAI2, it may cause problems for quality control of specific
activity. The stability of the a-conjugate is also a cause for concern.
Some 20% of activity is lost in serum at 371C within 1 half-life.
More stable conjugation is desired.
Minimal toxicity of
213Bi-PAI2 was observed in mice up to a
total activity of 6mCikg
 1. This dose level is expected to be more
than adequate for human use, and compares with 1mCikg
 1
reported for
213Bi-MAb in a phase 1 clinical trial by the Memorial
group (Jurcic et al, 2002).
The biodistribution of
213Bi-PAI2 in mice showed that the
kidneys received the highest dose (450% after 25min). Further,
the kidneys continued to accumulate activity up to 100min. This
result may have implications for the induction of secondary renal
cancer at higher doses.
Resection and histopathology of the 2-day postinoculation
breast cancer model showed abundant isolated cells and clusters
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Figure 2 Biodistribution study of
213Bi-PAI2 in nude mice. The kidneys
receive more than 50% of the radiation exposure after 30min.
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Figure 3 uPA expression in 2 days MDA-MB-231 breast cancer cells
inoculation model sections. The sections stained with MAb #394 are
positive to uPA Mab (A) while the control sections with no primary
antibody are negative to uPA MAb light grey (B). The dark grey colour
indicates positive cancer cells. Isolated cells and cell clusters are apparent,
with no evidence of capillary growth. Magnification: A, B 100.
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Figure 4 The effect of a single dose of
213Bi-PAI2 on tumour growth of
s.c. 2 days MDA-MB-231 breast cancer cells in nude mice with local and i.p.
injection in mice and the PAI2 blocking experiment. (A) Bilateral single local
injections each of 50mCi
213Bi-PAI2(.)o r5 0mCi
213Bi-BSA (m) and the
same volume of PBS buffer (’). (B) 100mCi i.p. administration of
213Bi-
PAI2 (.) or the same activity of
213Bi-BSA (m) and the same volume of
PBS buffer (’). (C) Pre-injection of PAI2, followed by 100mCi of
213Bi-
PAI2, allows all tumours to grow to the terminating end point at 30–40
days.
213Bi-PAI2 alone inhibits the growth of eight out of 10 tumours to 60
days (m) while the ‘blocked’ mice with 2 PAI2 (.), 3 PAI2 (E) and
4 PAI2 (K) can only survive up to 40 days. This blocking study shows
that uPA receptor sites on the MDA-MB-231 cells are saturated at twice
the therapeutic PAI2 dose of 100mgml
 1. No death related to toxicity
occurred. Data are expressed as the mean7s.e.m. for five tumours in each
case.
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sof cancer cells at the inoculation site, but no evidence for capillary
formation was found. This model is therefore expected to simu-
late micrometastatic cancer. Our in vivo studies revealed that
213Bi-PAI2 can target isolated cells and preangiogenic cell clusters.
Local therapy required only 25mCi of a-PAI2 to achieve complete
inhibition of tumorigenesis.
213Bi-PAI2 was found to be increas-
ingly less effective in a single dose intralesional protocol as the
tumours grew in size.
A higher dose of 100mCi was required for a single systemic
administration to achieve B80% inhibition, and indications of a
dose-dependent response were seen. All control results were found
to be significantly different from the
213Bi-PAI2 data. The specific,
in vivo cytotoxicity of
213Bi-PAI2 against the uPA receptor was
directly tested by preinjection of increasing concentrations of
PAI2, before
213Bi-PAI2 administration. Tumours grew in all
‘blocked’ mice, which were euthanised according to protocol at
30–40 days, whereas only two out of 10 tumours grew in the
unblocked
213Bi-PAI2 mice.
Our results clearly indicate that PAI2 can target membrane-
bound uPA receptors, deliver a particles to MDA-MB-231
metastatic breast cancer cells and regress tumour growth through
local or systemic injections. The exact mechanism of cell
killing has not been investigated. Macklis et al (1992) demon-
strated that a-particle radioimmunotherapy can induce apoptosis
in murine lymphoma cells. Using the
213Bi-PAI2 conjugate, we
have also demonstrated that
213Bi-PAI2 can induce a high
percentage of TUNEL-positive PC3 prostate cancer cells in vitro
and in vivo (Li et al, 2002b). These data suggest that apoptosis may
be the lethal pathway of
213Bi-PAI2 therapy for MDA-MB-231
breast cancer cells.
CONCLUSIONS
We have combined the cytotoxicity of an a-emitting radioisotope
(
213Bi) with the targeting potential of PAI2 to create the novel
construct
213Bi-PAI2, a potential new therapeutic agent for targeted
a therapy of breast and prostate cancer (Li et al, 2002b). The in
vitro cytotoxicity of
213Bi-PAI2 on breast cancer cells was shown to
be specific, indicating that the cell killing ability of
213Bi-PAI2
depends critically on the targeting of cells in a receptor-bound,
active uPA-dependent manner (Ranson et al, 2002). These in vivo
results show conclusively that
213Bi-PAI2 can target and kill
isolated cells and cell clusters, via local and systemic injection.
Further, as tumours in mice pretreated with PAI2 could not be
regressed, targeting of uPA/uPAR is implicated.
213Bi-PAI2 therapy
is therefore indicated for the control of micrometastic breast
cancer.
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Figure 5 Effect of a single i.p. injection of
213Bi-PAI2 with different activities on tumour growth in the 2-day MDA-MB-231 nude mice model. (A) 100mCi
of nonspecific
213Bi-9.2.27. (B)2 5mCi of
213Bi-PAI2. (C)5 0mCi
213Bi-PAI2. (D) 100mCi
213Bi-PAI2. A dose response is indicated, with eight out of 10
tumours being controlled at 100mCi of
213Bi -PAI2.
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